Figure S17 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Q: What type of study is this?

This is a Quantitative Study study.

Nikola Knoll; Sarah Masser; Blanka Bordas; Richard Y. Ebright; Guangyan Li; Devishi Kesar; Eliana Destefanis; Nicholas Kania; Diego J. Rodriguez; Jayu Jen; Sydney E. Zagar; Caleb Mensah; Zixin Chen; Samuel J. Moffitt; Erhumuoghene M. Enakireru; Yao He; Baomou Feng; Mira K. Chokshi; Cyrus Y. Jin; Srivatsan Raghavan; William R. Sellers; Kathleen M. Mulvaney

doi:10.1158/0008-5472.30125757

Key Points

The research identifies G1/S checkpoint as a key pathway responding to PRMT5i treatment in cancer cells.
CDKN2A/MTAP null and TP53WT cells showed different mRNA expression patterns, signaling distinct responses.
This study utilizes CRISPR technology to screen drug combinations and uncover effective treatments.
Findings imply that targeting p53-dependent genes could enhance therapeutic strategies for MTAP-deleted cancer.

Implication

Analysis identifies G1/S checkpoint response in CDKN2A/MTAP null cells, suggesting PRMT5i's role in targeting cancer.

Abstract

Figure S17. Differential mRNA expression of CDKN2A/MTAP null, TP53WT cells identifies p53-dependent genes and G1/S checkpoint as top responders to PRMT5i MRTX1719.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knoll et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa588dc https://doi.org/10.1158/0008-5472.30125757

View at Publisher

Ask AI

Bookmark

Share

Figure S17 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S17 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading